Trends in Immunology
ReviewGM-CSF in inflammation and autoimmunity
Section snippets
What are the responses to administered GM-CSF?
Several studies have monitored cellular changes and inflammatory responses following in vivo GM-CSF administration. Systemic or intraperitoneal GM-CSF injection in mice led to increased numbers of both circulating neutrophils and cycling peritoneal macrophages [11], as well as the development and differentiation of CD5? macrophages in the peritoneal cavity. GM-CSF rapidly primes mice for enhanced proinflammatory cytokine production in response to LPS and tumour necrosis factor-α (TNF-α) [12].
What are the in vitro responses to GM-CSF and which cells produce it?
Numerous examples of the in vitro action of GM-CSF on monocytes or macrophages, granulocytes and eosinophils have now been reported and only a few pertinent examples consistent with possible proinflammatory actions will be given. There is debate as to the extent of the direct induction of certain inflammatory mediators by GM-CSF-treated monocytes or macrophages [25]. Some data indicate that GM-CSF can induce the secretion of inflammatory cytokines [e.g. interleukin-1 (IL-1) and TNF-α], whereas
Is GM-CSF targetting effective in inflammation and autoimmunity?
Neither the presence of GM-CSF at sites of inflammation nor the elicitation of an inflammatory response by exogenous GM-CSF necessarily demonstrates that it is crucial to the progression of inflammatory reactions. Based in part on the evidence for the proinflammatory actions of GM-CSF and its increased production following IL-1 and TNF-α treatment by several cell types, we and others have proposed that GM-CSF allows communication between hemopoietic cells and local tissue cells during
Conclusions and unanswered questions
The precise mechanism(s) involved in the proinflammatory effect of GM-CSF in disease are yet to be defined. It is likely that GM-CSF has a central role in the local activation, recruitment and survival of macrophage lineage cells and PMNs, perhaps even contributing to macrophage proliferation at sites of inflammation (see, for example, [58]). Its role could extend both to the initiating and effector phases of disease; in addition, it could even function systemically. More information is needed
Acknowledgements
This work was supported by grants from the National Health and Medical Research Council of Australia. R. Sallay is thanked for typing the manuscript.
References (58)
- et al.
The nature and action of granulocyte-macrophage colony stimulating factors
Blood
(1980) GM-CSF rapidly primes mice for enhanced cytokine production in response to LPS and TNF
Cytokine
(1995)Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients
Blood
(1989)Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis
Blood
(1989)Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor
Blood
(1998)Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage
Cell
(1987)Colony stimulating factors, cytokines and monocyte-macrophages – some controversies
Immunol. Today
(1993)- et al.
Regulation of human monocyte DNA synthesis by colony-stimulating factors, cytokines, and cyclic adenosine monophosphate
Blood
(1992) Activation of human monocytes by granulocyte-macrophage colony-stimulating factor: increased urokinase-type plasminogen activator activity
Blood
(1991)Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor
Blood
(1990)